Screening Programme for Efficient Clinical Trial Access – lung cancer biomarker screening platform

The European Organisation for Research and Treatment of Cancer has announced that it will build a Screening Programme for Efficient Clinical Trial Access (SPECTA) for patients with lung cancer. This programme, SPECTAlung, will prospectively collect biological materials from patients who have been diagnosed with lung cancer, starting with non-small cell lung cancer and enable efficient clinical trial access for these patients. Read more here.